Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy — ONC-2010-001

Thymoma and Thymic Carcinoma Clinical Trial

Official title:
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy

Status Completed

Clinical Trial Summary

Given the high expression of IGF-1R and pAKT proteins in thymoma tissues, able to sensitize tumors to mTOR inhibition, and the anticancer activity of the mTOR inhibitors, clinical evaluation in thymoma and thymic carcinoma seems to be very interesting. Patients will receive continuous treatment with oral everolimus 10 mg once daily. Efficacy and safety profile of Everolimus will be evaluated.

Clinical Trial Description

Patients will receive continuous treatment with oral everolimus 10 mg once daily. Study drug will be self-administered orally (two 5 mg tablets) daily in a fasting state or with a light fat-free meal. Each cycle will be considered as 21 days of treatment; safety was assessed every 21 days. Tumor assessement will be done every two cycles. Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02049047
Study type	Interventional
Source	Istituto Clinico Humanitas
Contact
Status	Completed
Phase	Phase 2
Start date	February 2011
Completion date	January 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00003283` - Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma	Phase 2
Completed	`NCT00372840` - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer	N/A
Completed	`NCT00024076` - Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer	Phase 2
Completed	`NCT02636556` - Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors	N/A
Recruiting	`NCT02633514` - Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma	Phase 3
Recruiting	`NCT04554524` - Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma	Phase 4
Active, not recruiting	`NCT03663764` - Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor	Phase 2
Recruiting	`NCT06301945` - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors